Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 97 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chest Pain With Normal Coronary Angiography Clear all
Completed Phase 3 Interventional Results available

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

NCT03113760
View directory record Official record
Conditions
NLRC4-MAS, XIAP Deficiency
Interventions
Tadekinig alfa, 0.9% sodium chloride
Drug · Other
Lead sponsor
AB2 Bio Ltd.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 22, 2026, 3:16 AM EDT
Terminated Phase 2 Interventional Results available

A Placebo-Controlled Trial of CLBS16 in Subjects With Coronary Microvascular Dysfunction

NCT04614467
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Coronary Microvascular Disease, Microvascular Coronary Artery Disease
Interventions
CLBS16, Placebo
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • Hollywood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 3:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease

NCT00101517
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity, Metabolic Syndrome X
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
30 Years to 78 Years
Enrollment
4,024 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 22, 2026, 3:16 AM EDT
Recruiting Not applicable Interventional

Heart Disease of the Small Arteries in Women and Men

NCT00573027
View directory record Official record
Conditions
Heart Disease
Interventions
noninvasive tests
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome

NCT00362908
View directory record Official record
Conditions
Metabolic Syndrome X, Dyslipidemias
Interventions
Moderate Fat and Moderate Carbohydrate Diet, Low Fat and High Carbohydrate Diet
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
30 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Metformin Use in the Treatment of HIV

NCT00399360
View directory record Official record
Conditions
HIV Infections, Metabolic Syndrome X
Interventions
Metformin, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Phase 2 Interventional

Effects of Resistance and Aerobic Exercise on Cardiovascular Health

NCT00275145
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity, Hyperlipidemia, Insulin Resistance, Metabolic Syndrome X
Interventions
Resistance Training, Aerobic Exercise, Combo, Continued Sedentary lifestyle
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects

NCT03310359
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Astaxanthin, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults

NCT02347007
View directory record Official record
Conditions
Obesity, Overweight, Fatty Liver, Metabolic Syndrome X
Interventions
Almond, Cereal Bar
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 3:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cardiovascular Disease Risk Factors in Chinese American Immigrants

NCT00362128
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome X
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
2,072 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 22, 2026, 3:16 AM EDT
Terminated Not applicable Interventional Results available

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

NCT00477191
View directory record Official record
Conditions
Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
Interventions
Etanercept
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption

NCT02918422
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Nutritional and Dietary Manipulation
Other
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 22, 2026, 3:16 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients

NCT00909363
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
Interventions
Promacta, blood drawing in patients with WAS, blood drawing in healthy controls
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Months to 80 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional

Effects of TA-65, a Telomerase Activator on Metabolic Syndrome

NCT02531334
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
TA-65
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
32 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs

NCT06641596
View directory record Official record
Conditions
Overweight, Metabolic Syndrome X
Interventions
Placebo, Cr-400, Cr-800, PE-500, PE-1000
Dietary Supplement
Lead sponsor
Kerry Group P.L.C
Industry
Eligibility
30 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

NCT00455325
View directory record Official record
Conditions
Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions
Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 22, 2026, 3:16 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Insulin Resistance Study

NCT00614757
View directory record Official record
Conditions
Insulin Resistance, Metabolic Syndrome x
Interventions
N-acetylcysteine 20% 4ml, N-acetylcysteine 20% in 4 ml
Drug
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Weight Loss in Diabetic, Older Obese Adults

NCT00108329
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
Weight Loss
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 22, 2026, 3:16 AM EDT
Completed No phase listed Observational

MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR

NCT06139094
View directory record Official record
Conditions
Ischemic Heart Disease, Coronary Microvascular Disease, Angina
Interventions
CardioFlux Magnetocardiography
Device
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Gainesville, Florida • Detroit, Michigan • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 22, 2026, 3:16 AM EDT
Suspended Phase 3 Interventional

Efficacy of Topiramate for Weight Loss in Subjects With Metabolic Syndrome

NCT00243984
View directory record Official record
Conditions
Metabolic Syndrome X, Diabetes Mellitus, Type 2
Interventions
topiramate
Drug
Lead sponsor
Northeastern Ohio Universities College of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Akron, Ohio • Canton, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2007 · Synced Oct 22, 2026, 3:16 AM EDT
Terminated Phase 3 Interventional

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

NCT00228176
View directory record Official record
Conditions
Carotid Artery Plaque, Arteriosclerosis, Obesity, Metabolic Syndrome X
Interventions
Rimonabant, Placebo (for Rimonabant)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 22, 2026, 3:16 AM EDT
Recruiting Phase 1 Interventional

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

NCT06600178
View directory record Official record
Conditions
Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
Interventions
Brenzavvy (bexagliflozin), 20 mg Oral Tablet, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 3:16 AM EDT
Completed Phase 3 Interventional

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

NCT03512314
View directory record Official record
Conditions
XIAP Deficiency, NLRC4-MAS
Interventions
Tadekinig alfa
Drug
Lead sponsor
AB2 Bio Ltd.
Industry
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
La Jolla, California • Gainsville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 22, 2026, 3:16 AM EDT